Autolus Therapeutics 향후 성장
Future 기준 점검 2/6
Autolus Therapeutics (는) 각각 연간 47% 및 37.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 50.9% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -24.3% 로 예상됩니다.
핵심 정보
47.0%
이익 성장률
50.95%
EPS 성장률
| Biotechs 이익 성장 | 25.4% |
| 매출 성장률 | 37.6% |
| 향후 자기자본이익률 | -24.29% |
| 애널리스트 커버리지 | Good |
| 마지막 업데이트 | 15 May 2026 |
최근 향후 성장 업데이트
Recent updates
내러티브 업데이트 • May 18
AUTL: Early Commercial Traction And Cost Actions Will Support A Brighter Outlook
Analysts have adjusted their fair value estimate for Autolus Therapeutics to $11.00 from $13.00, citing updated assumptions around revenue growth, profitability, and future P/E, along with recent shifts in Street price targets following the Q1 report and Aucatyzl launch trends in the U.S. and UK. Analyst Commentary Recent Street commentary reflects a mix of optimism and recalibration around Autolus Therapeutics, with bullish analysts pointing to early commercial trends for Aucatyzl as a key driver for their views on valuation and execution.
내러티브 업데이트 • May 03
AUTL: Rebased Profit Assumptions Set Stage For Future Upside Execution
Analysts have reduced their price targets on Autolus Therapeutics by $2 to $3, citing updated assumptions on discount rates, profit margins, and future P/E levels that temper prior expectations. Analyst Commentary Bullish Takeaways Bullish analysts see the updated discount rates and profit margin assumptions as a reset that can make future execution milestones more impactful for valuation, rather than relying on aggressive prior models.내러티브 업데이트 • Apr 18
AUTL: Higher Risk Assumptions Will Still Support Upside Potential
Analysts have modestly lifted their fair value estimate for Autolus Therapeutics from $8.79 to $8.81, tying the change to updated assumptions for discount rates, revenue growth, profit margins, and future P/E, along with recent price target revisions from the Street. Analyst Commentary Recent Street research has focused on recalibrating price targets for Autolus Therapeutics, which feeds directly into the modest change in fair value.내러티브 업데이트 • Mar 31
AUTL: Lower 2026 Sales Guidance Will Still Support Upside Potential
Analysts have trimmed their price targets on Autolus Therapeutics by $2 to $3 following updated 2026 Aucatzyl sales guidance of $120M to $135M, as well as a recalibration of revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research notes highlight a mixed but focused view on Autolus Therapeutics, centered on execution against updated Aucatzyl sales guidance, cost structure, and how these flow through to valuation assumptions.Seeking Alpha • Mar 27
Autolus Therapeutics: Q4 Earnings Highlight Importance Of Autoimmune Data Catalysts
Summary Autolus Therapeutics plc maintains a Hold rating due to a challenging risk/reward profile despite strong clinical data for Aucatzyl in r/r B-ALL. 2026 guidance targets $120–$135m in product revenues and a shift to positive gross margin, with AUTL's cash runway projected into Q4 2027. Key catalysts include pediatric ALL Phase 2 data (2027) and initial MS autoimmune data (late 2026), both with significant upside potential. Competitive pressures, funding needs beyond 2027, and uncertain commercial uptake in cell therapy remain material risks for AUTL. Read the full article on Seeking Alpha분석 기사 • Feb 03
The Market Doesn't Like What It Sees From Autolus Therapeutics plc's (NASDAQ:AUTL) Revenues Yet As Shares Tumble 26%
Autolus Therapeutics plc ( NASDAQ:AUTL ) shareholders won't be pleased to see that the share price has had a very rough...분석 기사 • Dec 20
Autolus Therapeutics plc's (NASDAQ:AUTL) Shares Bounce 28% But Its Business Still Trails The Industry
Autolus Therapeutics plc ( NASDAQ:AUTL ) shares have had a really impressive month, gaining 28% after a shaky period...새로운 내러티브 • Aug 17
Robust Clinical Uptake Will Expand Advanced Cancer Therapy Adoption
Key Takeaways Accelerating adoption, regulatory progress, and expanded clinical indications position Autolus for increased market share and long-term revenue growth in advanced cancer therapies. Improved manufacturing efficiency and financial discipline strengthen margins, enabling investment in innovation and geographic expansion while supporting sustained profitability.분석 기사 • Apr 04
Industry Analysts Just Upgraded Their Autolus Therapeutics plc (NASDAQ:AUTL) Revenue Forecasts By 12%
Celebrations may be in order for Autolus Therapeutics plc ( NASDAQ:AUTL ) shareholders, with the analysts delivering a...Seeking Alpha • Mar 04
Autolus Therapeutics: Beaten Down, Cash Rich, Poised To Launch A CAR-T Cell Therapy
Summary Autolus Therapeutics' main focus is on obe-cel, a CAR T-cell therapy for B-cell ALL, with a strong likelihood of approval. AUTL has $657.1 million in cash, providing a cash runway of approximately 3 years, alleviating immediate financial concerns. The company faces significant competition in the CD19 CAR T-cell therapy market, making sales execution crucial for success. Despite the competitive landscape, AUTL's broad pipeline and recent approval of obe-cel position it well for future growth. Read the full article on Seeking AlphaSeeking Alpha • Feb 05
Autolus Therapeutics Will Remain Depressed For A While
Summary Autolus Therapeutics' obe-cel, branded Aucatzyl, is the first CAR-T therapy approved without a REMS, highlighting its safety and unique mechanism. Despite initial stock surge post-approval, AUTL's stock has steadily declined due to market skepticism on CAR-T's financial efficiency and pre-approval fundraising. AUTL's financials show a strong cash position but poor market performance, with the stock trading below cash value, excluding debt. The market demands sustained earnings and cautious fund-raising, suggesting AUTL's stock will remain depressed for the next 3-4 years. Read the full article on Seeking Alpha분석 기사 • Jan 07
Is Autolus Therapeutics (NASDAQ:AUTL) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Nov 21
AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market
Summary Autolus Therapeutics' AUCATZYL, approved by the FDA for relapsed/refractory B-cell ALL, shows strong potential despite safety concerns. The Company’s Obe-cel family and oncology pipeline include multiple catalysts for 2025, expanding potential indications in autoimmune diseases and hematologic malignancies. AUTL's cash runway of 1.9 years and no financial debt provide a solid financial foundation to support AUCATZYL's commercialization and future growth. Key risks include scaling manufacturing, securing insurance coverage, and expanding treatment centers, but these are manageable, supporting a bullish long-term outlook. Autolus's valuation appears undervalued given AUCATZYL's market potential and robust pipeline, including multiple CAR T-cell therapies in various trial stages. Read the full article on Seeking AlphaSeeking Alpha • Sep 06
Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case
Summary Autolus Therapeutics plc has a PDUFA date upcoming for its cell therapy obe-cel, indicated for B-ALL. The FDA will decide whether to approve the drug for commercial use. There is already a cell therapy approved in this indication, as well as Amgen's blincyto, but obe-cel's safety and efficacy profile appears strong. Autolus has taken its time gathering the data required to push for approval, but now it has US and EU approval in its sights. An intriguing secondary catalyst is obe-cel in autoimmune disease systemic lupus erythematosus - positive data could send the share price soaring. I have followed Autolus for some time, and my “buy” calls have not come off — but I remain optimistic there is a cell therapy player of note here and I am keeping the faith. Read the full article on Seeking Alpha분석 기사 • Aug 15
Is Autolus Therapeutics (NASDAQ:AUTL) Using Debt Sensibly?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Jul 31
Autolus Therapeutics: Major Inflection Point On The Horizon
Summary Today, we are putting T cell developmental firm Autolus Therapeutics plc back in the spotlight for the first time in a year and a half. The company could garner its first FDA approval later this year, and recently signed an enhanced partnership arrangement with a large player in the biotech space. An updated analysis around Autolus Therapeutics follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • May 14
Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity
Summary Autolus Therapeutics now has years of operational runway after recent financing. Operating expenses are manageable, with numerous pipeline projects in the hopper. Autolus likely has an approved therapy on their hands, just waiting for the November action date to realize it. Read the full article on Seeking Alpha분석 기사 • Nov 06
We're Hopeful That Autolus Therapeutics (NASDAQ:AUTL) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...분석 기사 • Jun 26
Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2028 | 321 | -131 | N/A | N/A | 6 |
| 12/31/2027 | 193 | -189 | -127 | N/A | 9 |
| 12/31/2026 | 129 | -236 | N/A | N/A | 9 |
| 3/31/2026 | 93 | -289 | N/A | N/A | N/A |
| 12/31/2025 | 75 | -288 | -311 | -284 | N/A |
| 9/30/2025 | 51 | -225 | -306 | -254 | N/A |
| 6/30/2025 | 30 | -228 | -312 | -263 | N/A |
| 3/31/2025 | 9 | -238 | -284 | -241 | N/A |
| 12/31/2024 | 10 | -221 | -241 | -206 | N/A |
| 9/30/2024 | 10 | -270 | -206 | -193 | N/A |
| 6/30/2024 | 10 | -234 | -161 | -157 | N/A |
| 3/31/2024 | 10 | -221 | -152 | -144 | N/A |
| 12/31/2023 | 2 | -208 | -157 | -146 | N/A |
| 9/30/2023 | 6 | -158 | -145 | -135 | N/A |
| 6/30/2023 | 7 | -155 | -142 | -127 | N/A |
| 3/31/2023 | 7 | -152 | -133 | -120 | N/A |
| 12/31/2022 | 6 | -149 | -123 | -112 | N/A |
| 9/30/2022 | 3 | -164 | -119 | -107 | N/A |
| 6/30/2022 | 1 | -155 | -119 | -110 | N/A |
| 3/31/2022 | 2 | -146 | -123 | -116 | N/A |
| 12/31/2021 | 2 | -142 | -127 | -118 | N/A |
| 9/30/2021 | 3 | -143 | -149 | -136 | N/A |
| 6/30/2021 | 3 | -147 | -154 | -141 | N/A |
| 3/31/2021 | 2 | -145 | -145 | -131 | N/A |
| 12/31/2020 | 2 | -142 | -132 | -118 | N/A |
| 9/30/2020 | 2 | -140 | -134 | -123 | N/A |
| 6/30/2020 | 1 | -130 | -120 | -109 | N/A |
| 3/31/2020 | 1 | -127 | -113 | -99 | N/A |
| 12/31/2019 | 3 | -124 | N/A | -101 | N/A |
| 9/30/2019 | 3 | -104 | N/A | -88 | N/A |
| 6/30/2019 | 3 | -89 | N/A | -72 | N/A |
| 3/31/2019 | 3 | -68 | N/A | -61 | N/A |
| 12/31/2018 | 1 | -58 | N/A | -43 | N/A |
| 9/30/2018 | 1 | -45 | N/A | -32 | N/A |
| 6/30/2018 | 1 | -41 | N/A | N/A | N/A |
| 3/31/2018 | 2 | -38 | N/A | N/A | N/A |
| 12/31/2017 | 2 | -29 | N/A | N/A | N/A |
| 9/30/2017 | 2 | -20 | N/A | -16 | N/A |
| 9/30/2016 | 1 | -13 | N/A | -10 | N/A |
| 9/30/2015 | 0 | -7 | N/A | -3 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: AUTL 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 vs 시장: AUTL 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
고성장 수익: AUTL 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 대 시장: AUTL 의 수익(연간 37.6%)이 US 시장(연간 11.7%)보다 빠르게 성장할 것으로 예상됩니다.
고성장 매출: AUTL 의 수익(연간 37.6%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: AUTL는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/21 10:42 |
| 종가 | 2026/05/21 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Autolus Therapeutics plc는 16명의 분석가가 다루고 있습니다. 이 중 9명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| James Shin | Deutsche Bank |
| Rajan Sharma | Goldman Sachs |
| Emily Bodnar | H.C. Wainwright & Co. |